Dark

GBT
Global Blood Therapeutics, Inc.
stock NASDAQ

Inactive

May 23, 2025

85.95USD-1.995%(-1.75)30,418

Pre-market

0.00USD-100.000%(-87.70)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 12, 2022

04:32PM EST Guerbet Announces Appointment of Jared Houk as Commercial Vice President for PR Newswire

Jan 10, 2022

09:07AM EST Global Blood Therapeutics Says Co's Oxbryta Tablets For Oral Suspension Now Available For Patients With Sickle Cell Disease In U.S. Benzinga

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced Oxbryta (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and Drug Administration (FDA), is now available through GBTs specialty pharmacy partner network in the United States. GlobeNewswire Inc

Jan 6, 2022

08:00AM EST GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Jan 4, 2022

12:02PM EST Guerbet: 2021 Corporate Social Responsibility GlobeNewswire Inc

08:00AM EST Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T. GlobeNewswire Inc

Dec 21, 2021

04:54AM EST SVB Leerink Maintains Outperform on Global Blood Therapeutics, Lowers Price Target to $53 Benzinga

Dec 20, 2021

05:27AM EST FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years Benzinga

Dec 17, 2021

02:09PM EST Global Blood Therapeutics Confirms Earlier Report FDA Approves Supplemental New Drug Application For Expanded Indication Of Oxbryta For Children As Young As 4 Years Of Age With Sickle Cell Disease Benzinga

02:05PM EST U.S. FDA Approves Supplemental New Drug Application for Expanded GlobeNewswire Inc

01:40PM EST Global Blood Therapeutics Gets FDA Approval Of Oxbryta For Treatment Of Sickle Cell Disease In Children Ages 4-11 Benzinga

10:36AM EST Global Blood Therapeutics Reports Received Positive European Medicines Agency Committee For Medicinal Products For Human Use Opinion For Its Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older Benzinga

10:33AM EST European Commission decision on marketing authorization anticipated first quarter of 2022 GlobeNewswire Inc

Dec 15, 2021

01:04AM EST GBT Announces Pricing of Upsized Offering of $300.0 Million of GlobeNewswire Inc

Dec 14, 2021

07:28AM EST GBT Announces Proposed Offering of $250.0 Million of Convertible GlobeNewswire Inc

04:49AM EST SVB Leerink Maintains Outperform on Global Blood Therapeutics, Raises Price Target to $56 Benzinga

01:00AM EST Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement PR Newswire

Dec 13, 2021

09:11AM EST GBT Highlights Presentation Of Results From Phase 1 Study Of GBT021601 At ASH Meeting Benzinga

09:07AM EST Adam Feuerstein Tweets 'More potent version of Global Blood $GBT sickle-cell drug improves hemoglobin response in small study https://statnews.com/2021/12/13/more-potent-global-blood-sickle-cell-drug-improves-hemoglobin-response/ #ASH21' Benzinga

09:00AM EST GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GlobeNewswire Inc

Dec 12, 2021

10:05AM EST GBT Presented Positive New Data on Oxbryta (voxelotor) in Patients with Sickle Cell Disease at ASH 2021; Said Real-world Experience Study of More Than 3,100 Patients Demonstrates Statistically Significant Reductions in Transfusions, Vaso-occlusive Crises and Hospitalizations in Patients Treated With Oxbryta Benzinga

09:00AM EST Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients treated with Oxbryta GlobeNewswire Inc

Dec 10, 2021

12:59PM EST Global Blood Therapeutics Earnings Perspective: Return On Capital Employed Benzinga

Dec 9, 2021

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that on December 1, 2021,the compensation committee of GBTs board of directors granted24 new employees restricted stock units for an aggregate of 80,270 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

Dec 7, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 Benzinga

07:15AM EST William Blair Upgrades Global Blood Therapeutics to Outperform Benzinga

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

08:02AM EST GBT Supports the ASH Research Collaborative's Data Hub Sickle Cell Disease PR Newswire

08:00AM EST GBT Supports the ASH Research Collaboratives GlobeNewswire Inc

Nov 24, 2021

08:09AM EST GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference Dec. 1 Benzinga

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 11:45 a.m. ET. GlobeNewswire Inc

Nov 12, 2021

08:00AM EST GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire Inc

Nov 8, 2021

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onNovember 1, 2021,the compensation committee of GBTs board of directors grantedeight new employees restricted stock units for an aggregate of 16,350 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

Nov 5, 2021

09:44AM EDT RBC Capital Maintains Outperform on Global Blood Therapeutics, Lowers Price Target to $64 Benzinga

09:24AM EDT Global Blood Therapeutics Q3 EPS $(1.13) Misses $(1.11) Estimate, Sales $52.05M Miss $53.70M Estimate Benzinga

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 1, 2021

08:00AM EDT Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honors Oxbryta as the Best Biotechnology Product for 2021 GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

08:00AM EDT Company to also host R&D Day on Thursday, November 11 in New York City and via video webcast GlobeNewswire Inc

Oct 21, 2021

11:46AM EDT Sustained level of activity in Q3 2021 GlobeNewswire Inc

Oct 7, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 Benzinga

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onOctober 1, 2021,the compensation committee of GBTs board of directors granted22 new employees restricted stock units for an aggregate of 54,750 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

05:03AM EDT Jefferies Initiates Coverage On Global Blood Therapeutics with Buy Rating, Announces Price Target of $68 Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 29, 2021

12:01PM EDT Guerbet contributes to the NH TherAguix IPO on Euronext Growth, a specialist in innovative biotechnologies for precision radiotherapy GlobeNewswire Inc

Sep 28, 2021

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 22, 2021

11:54AM EDT Guerbet: 2021 half-year results GlobeNewswire Inc

Sep 20, 2021

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor Global Healthcare Conference on Monday, September 27, 2021, at 2:40 p.m. ET. GlobeNewswire Inc

Sep 14, 2021

11:00AM EDT GBT Establishes The GBT Foundation to Improve the Health and GlobeNewswire Inc

Sep 9, 2021

08:00AM EDT GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Sep 8, 2021

05:05PM EDT GBT and Sickle Cell Disease Association of America to Host 10th GlobeNewswire Inc

Sep 7, 2021

09:33AM EDT Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use Benzinga

08:18AM EDT Global Blood Therapeutics: FDA Accepts Priority Review SNDA For Oxbryta For Sickle Cell Disease In Children Ages 4-11 RTTNews

08:10AM EDT Global Blood Therapeutics Announces FDA Has Accepted For Priority Review Supplemental New Drug Application For Oxbryta Benzinga

08:00AM EDT New Drug Application for Oxbryta dispersible tablets also accepted for priority review GlobeNewswire Inc

Sep 2, 2021

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences: GlobeNewswire Inc

Aug 20, 2021

01:49PM EDT Return on Capital Employed Insights for Global Blood Therapeutics Benzinga

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

03:23PM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021 Benzinga

Aug 12, 2021

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onAugust 1, 2021,the compensation committee of GBTs board of directors granted12 new employees restricted stock units for an aggregate of 33,050shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

Aug 4, 2021

10:34AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021 Benzinga

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021, at 2:20 p.m. ET. GlobeNewswire Inc

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

05:29AM EDT Truist Securities Upgrades Global Blood Therapeutics to Buy, Raises Price Target to $50 Benzinga

Aug 3, 2021

04:50PM EDT Global Blood Therapeutics Q2 EPS $(1.12) Beats $(1.19) Estimate, Sales $47.55M Beat $43.84M Estimate Benzinga

04:05PM EDT Achieved Oxbryta (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year GlobeNewswire Inc

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 23, 2021

11:16AM EDT Roth Capital Reiterates Buy Rating On Global Blood Therapeutics Inc With $124 Price Target Benzinga

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 22, 2021

11:47AM EDT Guerbet: Revenue at June 30, 2021 GlobeNewswire Inc

10:03AM EDT Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years Benzinga

07:00AM EDT Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta (voxelotor) in Children with SCD Ages 4 to 11 GlobeNewswire Inc

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 9, 2021

08:00AM EDT GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Jul 1, 2021

11:05AM EDT Global Blood Therapeutics: Return On Capital Employed Insights Benzinga

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 30, 2021

10:53AM EDT Looking Into Global Blood Therapeutics's Return On Capital Employed Benzinga

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

Jun 28, 2021

10:21AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021 Benzinga

05:40AM EDT JP Morgan Downgrades Global Blood Therapeutics to Neutral, Announces $36 Price Target Benzinga

Jun 15, 2021

08:00AM EDT GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in GlobeNewswire Inc

Jun 14, 2021

07:08AM EDT GBT's Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK Benzinga

07:00AM EDT GBTs Voxelotor is First Sickle Cell Disease GlobeNewswire Inc

Jun 11, 2021

03:00AM EDT Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation GlobeNewswire Inc

Jun 4, 2021

08:00AM EDT GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Jun 1, 2021

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m. Eastern Time. GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 12, 2021

10:00AM EDT GBT Announces Upcoming Data Presentations at European Hematology GlobeNewswire Inc

May 7, 2021

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onMay 1, 2021, the compensation committee of GBTs board of directors granted 14 new employees restricted stock units for an aggregate of 26,450 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

03:03PM EDT Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug Benzinga

12:06PM EDT Canaccord Genuity Maintains Hold on Global Blood Therapeutics, Lowers Price Target to $40 Benzinga

08:39AM EDT Roth Capital Maintains Buy on Global Blood Therapeutics, Lowers Price Target to $124 Benzinga

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences: GlobeNewswire Inc

May 5, 2021

04:39PM EDT Global Blood Therapeutics Q1 EPS $(1.21) Misses $(1.01) Estimate, Sales $39.04M Miss $43.00M Estimate Benzinga

04:05PM EDT Achieved Oxbryta (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe GlobeNewswire Inc

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 4, 2021

08:00AM EDT GBT and Sickle Cell Disease Association of America Kick Off GlobeNewswire Inc

Apr 28, 2021

07:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after U.S. financial markets close. GlobeNewswire Inc

Apr 22, 2021

11:46AM EDT Guerbet: Q1 2021 revenue GlobeNewswire Inc

Apr 14, 2021

01:20PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021 Benzinga

06:18AM EDT A Peek Into The Markets: US Stock Futures Edge Higher; Bank Earnings In Focus Benzinga

06:11AM EDT SVB Leerink Initiates Coverage On Global Blood Therapeutics with Outperform Rating, Announces Price Target of $54 Benzinga

Apr 8, 2021

07:20AM EDT Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment Benzinga

03:00AM EDT Complete 72-Week Results from Phase 3 HOPE Study of GlobeNewswire Inc

Apr 5, 2021

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onApril 1, 2021, the compensation committee of GBTs board of directors granted 12 new employees restricted stock units for an aggregate of 47,750 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

Mar 29, 2021

02:26AM EDT Guerbet: Additional information related to 2021 financial outlook GlobeNewswire Inc

Mar 24, 2021

12:45PM EDT Guerbet: 2020 annual results GlobeNewswire Inc

Mar 18, 2021

07:10AM EDT Global Blood Therapeutics Adds Alexis Thompson To Board RTTNews

07:00AM EDT GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors GlobeNewswire Inc

Mar 16, 2021

09:19AM EDT GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi Benzinga

07:00AM EDT GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license GlobeNewswire Inc

Mar 12, 2021

08:58AM EST Wolfe Research Initiates Coverage On Global Blood Therapeutics with Outperform Rating, Announces Price Target of $67 Benzinga

Mar 8, 2021

08:46AM EST GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Mar 2, 2021

08:00AM EST GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in GlobeNewswire Inc

07:30AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021. A presentation by Ted W. Love, M.D., president and CEO of GBT, will be available at 7:00 a.m. ET. GlobeNewswire Inc

Feb 25, 2021

12:29PM EST Hearing SEC Will Investigate Tesla's Elon Musk Related To His Tweets On Dogecoin Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 24, 2021

04:44PM EST Recap: Global Blood Therapeutics Q4 Earnings Benzinga

04:42PM EST Global Blood Therapeutics Q4 EPS $(1.00) Misses $(0.94) Estimate, Sales $41.30M Beat $39.03M Estimate Benzinga

04:05PM EST Achieved Oxbryta (voxelotor) net revenues of $41.3 million in the fourth quarter and$123.8 million for full year 2020 GlobeNewswire Inc

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 23, 2021

10:28AM EST Preview: Global Blood Therapeutics's Earnings Benzinga

Feb 19, 2021

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences: GlobeNewswire Inc

Feb 17, 2021

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after U.S. financial markets close. GlobeNewswire Inc

Feb 11, 2021

11:45AM EST Guerbet: Revenue 2020 GlobeNewswire Inc

Feb 5, 2021

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onFebruary 1, 2021, the compensation committee of GBTs board of directors granted 14 new employees restricted stock units for an aggregate of 103,450 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

Feb 4, 2021

08:06AM EST GBT Says Initiates Expanded Access Protocol For Oxbryta In Pediatric Patients With Sickle Cell Disease In U.S. Benzinga

08:00AM EST GBT Initiates Expanded Access Protocol for Oxbryta GlobeNewswire Inc

Jan 27, 2021

07:08AM EST European Medicines Agency Accepts GBT's Marketing Authorization Application for Oxbryta for the Treatment of Hemolytic Anemia in Sickle Cell Disease Benzinga

07:00AM EST European Medicines Agency Accepts GBTs Marketing GlobeNewswire Inc

Jan 20, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2021 Benzinga

09:56AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

05:21AM EST Piper Sandler Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $50 Benzinga

Jan 7, 2021

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onJanuary 1, 2021, the compensation committee of GBTs board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

Jan 5, 2021

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 11:40 a.m. Eastern Time. GlobeNewswire Inc

Dec 16, 2020

12:46PM EST Morgan Stanley Maintains Equal-Weight on Global Blood Therapeutics, Lowers Price Target to $45 Benzinga

Dec 15, 2020

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that onDecember 1, 2020, the compensation committee of GBTs board of directors granted eight new employees restricted stock units for an aggregate of 54,675 shares of the companys common stock. These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan). GlobeNewswire Inc

06:17AM EST HC Wainwright & Co. Assumes Global Blood Therapeutics at Buy, Announces Price Target of $75 Benzinga

Dec 7, 2020

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development. GlobeNewswire Inc

Dec 6, 2020

10:00AM EST Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status GlobeNewswire Inc

10:00AM EST Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in First Half of 2021 GlobeNewswire Inc

Dec 3, 2020

09:56AM EST Benzinga's Top Upgrades, Downgrades For December 3, 2020 Benzinga

Dec 2, 2020

07:06AM EST GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States Benzinga

07:00AM EST Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older. GlobeNewswire Inc

Nov 25, 2020

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences: GlobeNewswire Inc

Nov 13, 2020

08:00AM EST Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 2:00 p.m. Eastern Time. GlobeNewswire Inc

Nov 12, 2020

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

Nov 9, 2020

08:00AM EST GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Nov 6, 2020

02:45PM EST Stocks Trading Near 52-Week Lows On Friday, Nov. 6, 2020: ASRT, KBLMU, PNRG, YGMZ, APRE, UHT, LAIX, CLI, CORR, ANIP, CCOI, KBLM, NYC, UTL, PEI, TIG, EYEG, PVL, ZSAN, TTNP, NBRV, SFT, WPG, IFS, COGT, LMNL, PRFX, GBT, FNHC, ASMB, EPZM, UCL Benzinga

02:33PM EST Yahoo Finance Trending Stocks For Friday, Nov. 6, 2020: TTD, ACB, SQ, ROKU, CVS, NET, AYX, PLTR, SNDL, PTON, GBT, SNAP, CRON, TLRY, UBER, HEXO, MAXR, TMUS, CGC, MOGO, EA, Z, GPRO, PS, ASMB, IPOB, COTY, UI Benzinga

02:31PM EST Mid-Afternoon Market Update: Nasdaq Turns Positive; Global Blood Therapeutics Shares Drop Following Q3 Results Benzinga

12:36PM EST Mid-Day Market Update: Crude Oil Down Over 4%; Modine Manufacturing Shares Spike Higher Benzinga

11:40AM EST Canaccord Genuity Maintains Hold on Global Blood Therapeutics, Lowers Price Target to $45 Benzinga

11:26AM EST Morgan Stanley Maintains Equal-Weight on Global Blood Therapeutics, Lowers Price Target to $67 Benzinga

10:30AM EST Shares of Global Blood Therapeutics, Inc. (GBT) tanked over 35% on Friday morning after third-quarter results missed the Street estimates. RTTNews

10:11AM EST Mid-Morning Market Update: Markets Open Lower; US Economy Adds 638,000 Jobs In October Benzinga

09:31AM EST Benzinga's Top Upgrades, Downgrades For November 6, 2020 Benzinga

09:19AM EST Roth Capital Maintains Buy on Global Blood Therapeutics, Lowers Price Target to $128 Benzinga

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

06:12AM EST Raymond James Downgrades Global Blood Therapeutics to Market Perform Benzinga

Nov 5, 2020

05:27PM EST Global Blood Therapeutics Earlier Reported Q3 EPS $(0.97) Misses $(0.73) Estimate, Sales $36.89M Miss $43.98M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

03:27PM EST GBT Announces Upcoming Virtual Oxbryta, Inclacumab And GBT021601 Data Presentations At 62nd American Society Of Hematology (ASH) Annual Meeting & Exposition Dec. 7 Benzinga

03:27PM EST CORRECTION: GBT Announces Upcoming Virtual Oxbryta, Inclacumab And GBT021601 Data Presentations At 62nd American Society Of Hematology (ASH) Annual Meeting & Exposition Dec. 7 Benzinga

03:13PM EST GBT Announces Upcoming Virtual Oxbryta, Inclacumab And GBT021601 Data Presentations At 62nd American Society Of Hematology (ASH) Annual Meeting & Exposition Nov. 7 Benzinga

03:11PM EST Abstracts Include 72-Week Analysis of Phase 3 HOPE Study SupportingLong-Term Use of Oxbryta (voxelotor) GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, after U.S. financial markets close. GlobeNewswire Inc

Oct 26, 2020

06:00AM EDT Real-world effectiveness data on Oxbryta (voxelotor) in the treatment of sickle cell disease featured as oral presentation GlobeNewswire Inc

Oct 22, 2020

11:45AM EDT Guerbet: Revenue at September 30, 2020 GlobeNewswire Inc

Oct 13, 2020

09:41AM EDT Morgan Stanley Maintains Equal-Weight on Global Blood Therapeutics, Lowers Price Target to $68 Benzinga

Oct 12, 2020

08:07AM EDT GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders for Development of Oxbryta Tablets Benzinga

08:00AM EDT Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Awardfor Industry Innovation from the National Organization for Rare Disorders (NORD). GBT received the award for Oxbryta (voxelotor) tablets at a virtual event on October 9, 2020, following NORDs annual Rare Disease and Orphan Products Breakthrough Summit. GlobeNewswire Inc

Oct 6, 2020

10:14AM EDT Benzinga's Top Upgrades, Downgrades For October 6, 2020 Benzinga

08:29AM EDT Evercore ISI Group Initiates Coverage On Global Blood Therapeutics with Outperform Rating, Announces Price Target of $102 Benzinga

Oct 5, 2020

08:00AM EDT GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Sep 23, 2020

11:46AM EDT Guerbet: 2020 Half-year results GlobeNewswire Inc

Sep 9, 2020

08:00AM EDT Keynote Address by U.S. Assistant Secretary for Health Admiral Brett P. Giroir, M.D. GlobeNewswire Inc

Sep 8, 2020

04:07PM EDT GBT, Biopharma-MEA Enter Agreement To Distribute Oxbryta In Six Middle Eastern Countries Benzinga

04:05PM EDT More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates GlobeNewswire Inc

Sep 4, 2020

08:00AM EDT GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Sep 3, 2020

08:00AM EDT Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences: GlobeNewswire Inc

Aug 25, 2020

11:53AM EDT Why Global Blood Therapeutics Is Trading Higher Today Benzinga

09:35AM EDT Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga

06:50AM EDT Raymond James Initiates Coverage On Global Blood Therapeutics with Outperform Rating, Announces Price Target of $115 Benzinga

Aug 7, 2020

08:00AM EDT GBT Announces New Employment Inducement Grants GlobeNewswire Inc

Aug 6, 2020

10:13AM EDT Stifel Maintains Buy on Global Blood Therapeutics, Raises Price Target to $118 Benzinga

Aug 5, 2020

04:18PM EDT Global Blood Therapeutics Q2 EPS $(0.86) Beats $(1.15) Estimate, Sales $31.50M Beat $18.81M Estimate Benzinga

04:01PM EDT Achieved Oxbryta (voxelotor) net revenues of $31.5 million, with approximately 1,000 new patient prescriptions GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 30, 2020

Jul 29, 2020

08:00AM EDT Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, after U.S. financial markets close. GlobeNewswire Inc

Jul 23, 2020

11:46AM EDT Guerbet: Revenue at June 30, 2020 GlobeNewswire Inc

Jul 20, 2020

09:18AM EDT Roth Capital Initiates Coverage On Global Blood Therapeutics with Buy Rating, Announces Price Target of $129 Benzinga

Jul 15, 2020

12:00PM EDT Guerbet Optimizes its Industrial NetworkSale of the Montreal pharmaceutical site GlobeNewswire Inc

Jul 13, 2020

09:32AM EDT Benzinga's Top Upgrades, Downgrades For July 13, 2020 Benzinga

07:38AM EDT B of A Securities Initiates Coverage On Global Blood Therapeutics with Buy Rating, Announces Price Target of $92 Benzinga